CardioDx gene-expression performs well in trial

17 November 2011 (Last Updated November 17th, 2011 18:30)

CardioDx's Corus CAD blood-based gene expression test has demonstrated superior performance in a trial.

CardioDx's Corus CAD blood-based gene expression test has demonstrated superior performance in a trial.

Corus CAD, a sex-specific blood-based test, can help clinicians and cardiologists evaluate whether a non-diabetic patient's symptoms are due to obstructive coronary artery disease.

The prospective, blinded, multicentre study is intended to validate the CardioDx blood-based gene expression test for eliminating obstructive coronary artery disease and to compare the diagnostic performance of Corus CAD to myocardial perfusion imaging.

COMPASS enrolled 537 stable patients with symptoms suggestive of coronary artery disease, and found 89% sensitivity and 96% negative predictive value with Corus CAD compared to 27% and 88% with myocardial perfusion imaging.

University of California-Irvine School of Medicine Nuclear cardiology education director Gregory Thomas said that the use of new gene expression test, followed by myocardial perfusion imaging will optimise diagnostic performance and the use of healthcare resources.

"COMPASS builds on previous results of the PREDICT trial. In this real-world patient population, the Corus CAD test demonstrates very high sensitivity and negative predictive value, enabling clinicians to rule out patients who do not have obstructive coronary artery disease with high accuracy," Thomas said.